[go: up one dir, main page]

KR840007106A - Method for preparing anti-tumor antibiotic tzopeptin E₂ - Google Patents

Method for preparing anti-tumor antibiotic tzopeptin E₂ Download PDF

Info

Publication number
KR840007106A
KR840007106A KR1019840000383A KR840000383A KR840007106A KR 840007106 A KR840007106 A KR 840007106A KR 1019840000383 A KR1019840000383 A KR 1019840000383A KR 840000383 A KR840000383 A KR 840000383A KR 840007106 A KR840007106 A KR 840007106A
Authority
KR
South Korea
Prior art keywords
methionine
cysteine
nutrient medium
luzopeptin
rujo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019840000383A
Other languages
Korean (ko)
Other versions
KR880001638B1 (en
Inventor
에이. 클라리즈 차알스 (외 3)
Original Assignee
원본미기재
브리스톨-마이어즈 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 브리스톨-마이어즈 컴페니 filed Critical 원본미기재
Publication of KR840007106A publication Critical patent/KR840007106A/en
Application granted granted Critical
Publication of KR880001638B1 publication Critical patent/KR880001638B1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음No content

Description

항종양성 항생 물질 투조펩틴 E2의 제조방법Method for preparing anti-tumor antibiotic tzopeptin E2

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 KBr중에서 과립화시킨 경우 루조펩틴 E2의 적외선 흡수 스펙트럼도이고,1 is an infrared absorption spectral diagram of luzopeptin E 2 when granulated in KBr,

제2도는 CDCl3에 용해시킨 루조펩틴 E2의 영자 자기공명 스펙트럼도이며,2 is an English magnetic resonance spectrum diagram of lupeptin E 2 dissolved in CDCl 3 ,

제3도는 CDCl3에 용해시킨 루조펩틴 E2의 탄소핵자기 공명 스펙트럼도이다3 is a carbon nuclear magnetic resonance spectrum diagram of lupeptin E 2 dissolved in CDCl 3 .

Claims (3)

악티노마두라 루조넬시스(Actinomadura luzonensis)ATCC 31491군주 또는 이 균주의 루조펩틴 E2생성변이 균주를 수면 아래 호기성 조건하에 탄소 및 질소의 등화원을 함유하는 수성 영양 배지중에서 상기루조펩틴 E2의 실질적인 양이 상기 미생물에 의해 상기 배치중에서 생성될 때까지 배양시키고, 상기 배지로부터 공생되는 물질이 없이 순수한 루조펩틴 E2를 분리하는 것을 특징으로 하는 다음 구조식의 항종양성 항생 물질 루조펩틴 E2의 제조방법.Actinoids Norma dura base jonel sheath (Actinomadura luzonensis) substantially of ATCC 31491 Monarch or the rujo peptin E 2 in an aqueous nutrient medium containing an equalizing source of carbon and nitrogen under aerobic conditions following a rujo peptin E 2 generated mutant strain of the strain sleep A method of preparing an anti-tumor antibiotic Luzopeptin E 2 having the following structure is characterized by culturing until the amount is produced in the batch by the microorganism, and separating pure Luzopeptin E 2 from the medium without symbiotic material. . 제1항에 있어서, 발효 단계의 영양 배지에 D,L-메티오닌, S-메틸-시스테인, S-에틸-L-시스테인, D,L-메티오닌, D-메티오닌, L-메티오닌, 아세틸-메티오닌, 2-아미노메탄에티올, 2-히드록시-4-(메틸티오)부티르산, D,L-O-메틸세린, L-시스테인 및 L-메티오닐 글리신 중에서 선정한황 함유 화합물을 첨가하는 것이 특징인 방법.The nutrient medium according to claim 1, wherein D, L-methionine, S-methyl-cysteine, S-ethyl-L-cysteine, D, L-methionine, D-methionine, L-methionine, acetyl-methionine, A method characterized by adding a sulfur-containing compound selected from 2-aminomethanethiol, 2-hydroxy-4- (methylthio) butyric acid, D, LO-methylserine, L-cysteine and L-methionyl glycine. 제1항에 있어서, 발효단계의 영양 배지에 D,L-메티오닌 또는 S-메틸-시스테인을 첨가하는 것이 특징인 방법The method of claim 1, wherein D, L-methionine or S-methyl-cysteine is added to the nutrient medium in the fermentation step. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019840000383A 1983-01-31 1984-01-28 Antitumor agent luzopeptin e2 and its preparation process Expired KR880001638B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46257783A 1983-01-31 1983-01-31
US462.577 1983-01-31
US462577 1983-01-31

Publications (2)

Publication Number Publication Date
KR840007106A true KR840007106A (en) 1984-12-05
KR880001638B1 KR880001638B1 (en) 1988-09-03

Family

ID=23836950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840000383A Expired KR880001638B1 (en) 1983-01-31 1984-01-28 Antitumor agent luzopeptin e2 and its preparation process

Country Status (15)

Country Link
JP (1) JPH0645638B2 (en)
KR (1) KR880001638B1 (en)
AU (1) AU566569B2 (en)
BE (1) BE898807A (en)
CA (1) CA1220746A (en)
CH (1) CH663415A5 (en)
DE (1) DE3403125A1 (en)
FR (1) FR2540116B1 (en)
GB (1) GB2134119B (en)
GR (1) GR81749B (en)
IT (1) IT1175927B (en)
MY (1) MY8800015A (en)
NL (1) NL8400237A (en)
SE (1) SE464582B (en)
ZA (1) ZA84613B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) * 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
GB2294265A (en) * 1994-10-20 1996-04-24 Merck & Co Inc Cyclic depsipeptides obtained from Actinomycete sp.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2050384B (en) * 1979-04-02 1983-04-07 Bristol Myers Co Antitumor antibacterial agents

Also Published As

Publication number Publication date
AU2372184A (en) 1984-08-02
JPH0645638B2 (en) 1994-06-15
IT1175927B (en) 1987-08-12
GB8402410D0 (en) 1984-02-29
GB2134119A (en) 1984-08-08
SE464582B (en) 1991-05-13
GB2134119B (en) 1986-04-30
BE898807A (en) 1984-07-31
FR2540116B1 (en) 1989-08-18
JPS59173091A (en) 1984-09-29
CH663415A5 (en) 1987-12-15
AU566569B2 (en) 1987-10-22
SE8400450D0 (en) 1984-01-30
NL8400237A (en) 1984-08-16
IT8419348A0 (en) 1984-01-27
CA1220746A (en) 1987-04-21
DE3403125A1 (en) 1984-10-31
MY8800015A (en) 1988-12-31
SE8400450L (en) 1984-08-01
GR81749B (en) 1984-12-12
ZA84613B (en) 1984-09-26
FR2540116A1 (en) 1984-08-03
KR880001638B1 (en) 1988-09-03

Similar Documents

Publication Publication Date Title
KR930006157A (en) Method for producing amino acid by fermentation
KR870008022A (en) Method for preparing L-threonine
KR840007257A (en) Rebeccamycin and its preparation
KR840005483A (en) A47934 Preparation of antibiotics
EP0088602A3 (en) Microbiological oxidation process
KR840007106A (en) Method for preparing anti-tumor antibiotic tzopeptin E₂
KR840002904A (en) Method for Decomposing Compounds Containing Methyl Group in Pseudomonas Microorganisms and Aqueous Solutions
KR870004132A (en) Biochemicals labeled with stable isotopes and their preparation
KR840004442A (en) Improved manufacturing method of lancassidine
KR900008047A (en) Method for preparing L-threonine
KR850001291A (en) Method for preparing polyether antibiotic X-14934A
KR860002575A (en) Preparation method of sapramycin A derivative
KR830007831A (en) Preparation of Antibiotic A-4696 Factor G
KR830005357A (en) How to prepare Nara
KR830010197A (en) How to prepare Nara
KR890014457A (en) Novel azoxy compound and preparation method thereof
KR900014583A (en) Microorganisms Producing L-lysine and Method of Making L-lysine Using the Same
KR830007840A (en) Method for preparing β-lactam compound
KR850003732A (en) Method for preparing antibiotic A39079 factor S-1
KR910002457A (en) Antiviral antibiotic BU-3889V
IL88088A (en) Microbiological process for making antibiotic uk-61,689,microorganisms useful therefor,and anticoccidial composition containing it
GB959108A (en) A method of producing l-threonine by fermentation
KR920009986A (en) Dainemycin C Antineoplastic Antibiotics
KR830000720A (en) New antibiotic neplanocene manufacturing method
KR840007437A (en) Preparation of Antibiotic A 51568 Factors A and B

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 19930811

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19940904

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19940904

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000